Three patient groups recently told a federal appeals court that a 340B rebate model “is essential to the effort to bring transparency to 340B.” One of those groups did not disclose its financial ties to drugmakers, and another is out of compliance with state public reporting laws.
Patient Groups Back Drugmakers in 340B Rebate Appeal, Without Disclosing Drug Industry Funding or Missed Compliance Deadline
Three patient groups are urging a federal appeals court to back drugmaker 340B rebate models they argue would bring transparency [...]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
